B

Brainstorm Cell Therapeutics
D

BCLI

1.73000
USD
-0.08
(-4.42%)
مغلق
حجم التداول
282
الربح لكل سهم
-2
العائد الربحي
-
P/E
-1
حجم السوق
9,866,927
أصول ذات صلة
    A
    APLS
    -0.850
    (-3.00%)
    27.510 USD
    A
    ASND
    -2.390
    (-1.54%)
    152.440 USD
    A
    ATHA
    -0.00750
    (-1.70%)
    0.43410 USD
    M
    MBIO
    0.01000
    (0.34%)
    2.92000 USD
    M
    MDB
    -16.73
    (-5.77%)
    273.35 USD
    Q
    QURE
    -0.130
    (-1.00%)
    12.840 USD
    R
    RYTM
    -1.660
    (-2.87%)
    56.090 USD
    V
    VYGR
    -0.04000
    (-0.94%)
    4.22500 USD
    المزيد
الأخبار المقالات

العنوان: Brainstorm Cell Therapeutics

القطاع: Healthcare
الصناعة: Biotechnology
Brainstorm Cell Therapeutics Inc is a biotechnology company. The company is developing novel adult stem cell therapies for debilitating neurodegenerative disorders such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Progressive Multiple Sclerosis (PMS), and Parkinson's disease (PD). Brainstorm's NurOwn, its proprietary process for the propagation of Mesenchymal Stem Cells (MSC) and differentiation into neurotrophic factor-(NTF) secreting cells (MSC-NTF), and their transplantation at, or near, the site of damage, offers the hope of more effectively treating neurodegenerative diseases.